Hims & Hers HealthHIMS
HIMS
About: Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
Employees: 1,637
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
228% more first-time investments, than exits
New positions opened: 131 | Existing positions closed: 40
57% more capital invested
Capital invested by funds: $2.52B [Q3] → $3.97B (+$1.45B) [Q4]
28% more funds holding
Funds holding: 304 [Q3] → 389 (+85) [Q4]
27% more repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 103
12.33% more ownership
Funds ownership: 65.82% [Q3] → 78.15% (+12.33%) [Q4]
0% more call options, than puts
Call options by funds: $384M | Put options by funds: $383M
25% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
24%
downside
Avg. target
$40
20%
upside
High target
$68
105%
upside
9 analyst ratings
2 positive
22%
5 neutral
56%
2 negative
22%
B of A Securities Allen Lutz 69% 1-year accuracy 11 / 16 met price target | 21%downside $26 | Underperform Maintained | 29 Apr 2025 |
Morgan Stanley Craig Hettenbach 14% 1-year accuracy 1 / 7 met price target | 21%upside $40 | Equal-Weight Maintained | 29 Apr 2025 |
TD Cowen Jonna Kim 75% 1-year accuracy 3 / 4 met price target | 9%downside $30 | Hold Downgraded | 29 Apr 2025 |
Citigroup Daniel Grosslight 40% 1-year accuracy 10 / 25 met price target | 24%downside $25 | Sell Maintained | 25 Apr 2025 |
Truist Securities Jailendra Singh 34% 1-year accuracy 12 / 35 met price target | 0%downside $33 | Hold Maintained | 10 Apr 2025 |
Financial journalist opinion
Based on 47 articles about HIMS published over the past 30 days
Positive
Zacks Investment Research
4 hours ago
Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?
Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
Positive
Zacks Investment Research
9 hours ago
Hims & Hers vs. Teladoc: Which Telehealth Stock Is the Better Buy Now?
Both HIMS and TDOC are technology-intensive healthcare companies that leverage their strengths in the digital health space to enhance their platforms. Which one is a better investment?
Positive
MarketBeat
12 hours ago
Hims & Hers Stock Soars on Novo Nordisk Collaboration
Every once in a while, investors come across some of the best names in a given industry, which then become subject to the best news and developments during a holding period. Today's best pick seems to be in the medical sector.
Positive
Fast Company
13 hours ago
Hims & Hers stock price soars after partnership with Novo Nordisk to offer weight-loss drug Wegovy
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordisk. That partnership will see Hims & Hers offer Novo Nordisk's weight-loss drug Wegovy through its platform.
Positive
Zacks Investment Research
16 hours ago
Hims & Hers Health (HIMS) Stock Jumps 23.0%: Will It Continue to Soar?
Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Positive
Seeking Alpha
1 day ago
Hims & Hers Health: GLP-1 Deals De-Risk The Story
Hims & Hers Health partners with Novo Nordisk to offer Wegovy, de-risking investment but not significantly altering the business focus on personalized healthcare solutions. The health and wellness platform already targeted $725 million in weight-loss sales this year, without including any branded GLP-1 sales. The company's core business remains robust, with significant contributions from sexual health, dermatology, and mental health, accounting for over $1.2 billion in 2024 sales.
Positive
The Motley Fool
1 day ago
Why Hims & Hers Health and LifeMD Are Skyrocketing Today
Shares of Hims & Hers Health (HIMS 25.46%) and LifeMD (LFMD 35.41%) are surging on Tuesday. The companie' stocks had jumped 24% and 34%, respectively, as of 3:15 p.m.
Positive
Proactive Investors
1 day ago
Hims & Hers stock pops on Novo Nordisk partnership
Hims & Hers (NYSE:HIMS) shares surged after it announced a partnership with Novo Nordisk that will allow it to offer the drugmaker's weight loss product Wegovy through its telehealth platform. Investors welcomed the collaboration, which positions Hims & Hers to participate directly in the fast-growing market for GLP-1 weight-loss drugs.
Positive
Benzinga
1 day ago
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.
Positive
Fox Business
1 day ago
Hims & Hers partners with Novo Nordisk to sell Wegovy
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Charts implemented using Lightweight Charts™